United States
LocationRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
GHISLAINE MAXWELL
|
Legal representative |
32
Very Strong
|
72 | |
|
person
Jeffrey Epstein
|
Legal representative |
13
Very Strong
|
10 | |
|
person
Epstein
|
Legal representative |
13
Very Strong
|
19 | |
|
person
MAXWELL
|
Legal representative |
12
Very Strong
|
9 | |
|
organization
Iran
|
Adversarial |
10
Very Strong
|
7 | |
|
person
Davis
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Bodmer
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Dreier
|
Legal representative |
10
Very Strong
|
4 | |
|
person
English
|
Legal representative |
10
Very Strong
|
4 | |
|
person
Boustani
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Torres
|
Legal representative |
10
Very Strong
|
4 | |
|
location
China
|
Unknown |
10
Very Strong
|
4 | |
|
person
Smith
|
Legal representative |
9
Strong
|
5 | |
|
person
Ms. Maxwell
|
Legal representative |
9
Strong
|
4 | |
|
location
China
|
Geopolitical rivals |
9
Strong
|
2 | |
|
person
Sampson
|
Legal representative |
8
Strong
|
4 | |
|
person
Carrillo-Villa
|
Legal representative |
8
Strong
|
2 | |
|
person
Petrov
|
Legal representative |
8
Strong
|
3 | |
|
person
Dominguez
|
Legal representative |
8
Strong
|
2 | |
|
person
Hung
|
Legal representative |
8
Strong
|
2 | |
|
person
Abdellatif El Mokadem
|
Legal representative |
8
Strong
|
2 | |
|
person
Rowe
|
Legal representative |
8
Strong
|
3 | |
|
person
Alindato-Perez
|
Legal representative |
8
Strong
|
2 | |
|
person
Crowell
|
Legal representative |
8
Strong
|
2 | |
|
person
Deutsch
|
Legal representative |
8
Strong
|
2 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Return to Afghanistan to oust Taliban regime | Afghanistan | View |
| N/A | Extradition proceedings | Proceedings in England and Wales in relation to US extradition requests for Ghislaine Maxwell. | England and Wales | View |
| N/A | N/A | Syrian civil uprising and potential use of chemical weapons by the Assad regime | Syria | View |
| N/A | N/A | U.S. involvement in Libya | Libya | View |
| N/A | N/A | Diplomatic crisis involving Israel, Turkey, and the U.S. | International | View |
| N/A | N/A | War with Iran | Iran | View |
| N/A | N/A | Potential military campaign against Iran | Iran | View |
| N/A | N/A | Proposed joint intelligence estimate session | Unspecified | View |
| N/A | N/A | Potential conflict with Iran | Middle East / Global | View |
| N/A | N/A | Signing of an agreement where Epstein acknowledges conditions, waives certain rights, and consent... | N/A | View |
| N/A | N/A | United States subjected South Korea to steel and aluminum tariffs. | N/A | View |
| N/A | N/A | Intensification of the trade war between the United States and China. | N/A | View |
| 2025-12-23 | N/A | China hit U.S. with $60 bn worth of tariffs | Global/Trade | View |
| 2025-11-19 | N/A | North Korea's mission to the UN accused the United States of being hell-bent on hostile acts. | United Nations | View |
| 2025-11-19 | N/A | North Korea’s mission to the UN accused the US of being 'hell-bent' on hostile acts. | United Nations | View |
| 2025-11-17 | N/A | U.S. slapped $200 bn worth of tariffs on China | Global/Economic | View |
| 2024-11-25 | N/A | Rehearing denied for United States v. Maxwell, 118 F.4th 256 (2d Cir. 2024). | Second Circuit | View |
| 2024-09-17 | N/A | Judgment entered for United States v. Maxwell, 118 F.4th 256 (2d Cir. 2024). | Second Circuit | View |
| 2024-01-01 | N/A | United States v. Maxwell, 118 F.4th 256 (2d Cir. 2024) case cited. | Second Circuit | View |
| 2024-01-01 | Legal decision | Decision in the case United States v. Johnson, 93 F.4th 605 (2024). | N/A | View |
| 2024-01-01 | N/A | U.S. v. Maxwell Decision | Second Circuit Court of App... | View |
| 2023-03-12 | Court argument | Argument date for the case United States v. Ghislaine Maxwell, Docket No. 22-1426. | United States Court of Appe... | View |
| 2023-02-07 | N/A | Legal case: United States v. Amani Investments, No. 2:23-cr-00014-JAM, ECF No. 8 | E.D. Cal. | View |
| 2023-01-01 | Legal case | Citation of United States v. Montague, 67 F.4th 520 (2d Cir. 2023). | 2d Cir. | View |
| 2023-01-01 | Legal proceeding | Court case: United States v. Nieves | 2d Cir. | View |
HOUSE_OVERSIGHT_031987.jpg
This document contains the text of a review for the 2010 documentary film 'Inside Job,' which analyzes the 2008 financial crisis. The text is followed by a strict confidentiality disclaimer identifying the communication as the property of Jeffrey Epstein and providing the contact email 'jeevacation@gmail.com'. The document bears the Bates stamp HOUSE_OVERSIGHT_031987.
HOUSE_OVERSIGHT_024722.jpg
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024721.jpg
This document is page 85 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It discusses the path to federal legalization, analyzing the roles of the DEA and FDA, the conflict between state and federal regulations, and the bureaucratic hurdles stalling the approval of cannabis-derived drugs under the leadership of Attorney General Jeff Sessions. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional oversight committee.
HOUSE_OVERSIGHT_024720.jpg
This document is page 84 of a 'Cannabis Investment Report' dated December 2017, published by Ackrell Capital, LLC. The text details the legal complexities of intellectual property protection for cannabis businesses, specifically discussing the USDA's Plant Variety Protection Act (PVPA) and the federal Trademark Act (Lanham Act). It highlights that federal trademark registration is generally unavailable for products that are illegal under federal law, though some ancillary products (like clothing) may be eligible. The page bears a 'HOUSE_OVERSIGHT_024720' stamp, indicating it was part of document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024719.jpg
This document is page 83 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the application of Section 280E of the tax code to cannabis businesses and discusses the Patent Act, listing several specific cannabis-related patents issued by the USPTO (including one held by the U.S. federal government) despite the drug's federal illegality. The document bears a House Oversight Committee Bates stamp, but contains no direct text references to Jeffrey Epstein or his associates on this specific page.
HOUSE_OVERSIGHT_024717.jpg
This document is page 81 of a 2017 report by Ackrell Capital titled 'U.S. Legal Landscape' (Chapter IV). It analyzes federal securities laws and bankruptcy laws specifically in the context of the cannabis industry, noting that while securities laws allow capital raising, bankruptcy protection is generally unavailable due to federal illegality. It cites the 2015 Arizona case 'In Re Medpoint Management, LLC' as a precedent for denying bankruptcy protection based on the 'unclean hands' doctrine.
HOUSE_OVERSIGHT_024716.jpg
This document is page 80 of a December 2017 Cannabis Investment Report by Ackrell Capital. It summarizes the findings of the California State Treasurer's Cannabis Banking Working Group regarding the banking difficulties faced by the cannabis industry and outlines recommendations for state and federal action. The lower half of the page provides a general overview of Federal Securities Law (1933 and 1934 Acts) and the role of the SEC. The document bears a House Oversight Committee Bates stamp, suggesting it was part of a larger document production, likely related to financial investigations.
HOUSE_OVERSIGHT_024715.jpg
This document is page 79 of a report by Ackrell Capital, titled 'Chapter IV U.S. Legal Landscape'. It presents data sourced from the Financial Crimes Enforcement Network regarding 'Marijuana-Related SAR Filings' between Q2 2014 and Q2 2017. The page argues that the increasing trend in these filings indicates cannabis businesses are accessing the federal banking system despite federal prohibitions. The document bears a 'HOUSE_OVERSIGHT_024715' Bates stamp.
HOUSE_OVERSIGHT_024713.jpg
This document is page 77 of a 2017 report by Ackrell Capital, LLC, discussing the U.S. legal landscape for the cannabis industry. It specifically details the Bank Secrecy Act (BSA), money laundering statutes, and the 2014 FinCEN Memo regarding how financial institutions should handle marijuana-related businesses and file Suspicious Activity Reports (SARs). The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a congressional investigation, though the text itself does not mention Jeffrey Epstein.
HOUSE_OVERSIGHT_024712.jpg
Page 76 of a December 2017 Cannabis Investment Report authored by Ackrell Capital. The text analyzes the regulatory landscape for cannabis-based foods and dietary supplements under the FD&C Act, specifically focusing on FDA and DEA policies regarding THC and CBD. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a congressional document production, though no specific individuals (including Epstein) are named on this page.
HOUSE_OVERSIGHT_024711.jpg
This document is page 75 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It details FDA regulations regarding 'off-label' prescriptions and specifically analyzes 'Cannabinoid-Based Drugs' such as Marinol, Syndros, Cesamet, Sativex, and Epidiolex. It discusses their scheduling under the Controlled Substances Act (CSA) and the status of their FDA approvals as of October 2017. The document bears a 'HOUSE_OVERSIGHT_024711' stamp, indicating it was part of a document production for the House Oversight Committee.
HOUSE_OVERSIGHT_024710.jpg
This document is page 74 of a 'Cannabis Investment Report' published by Ackrell Capital in December 2017. It details the regulatory framework for drugs under the FD&C Act, defining what constitutes a drug and outlining the FDA's four-step approval process (from animal testing to New Drug Application). The document bears a 'HOUSE_OVERSIGHT_024710' Bates stamp, indicating it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024707.jpg
This document is page 71 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the DOJ's 'Cole Memo' (2013) which outlined enforcement priorities for federal prosecutors regarding marijuana offenses. It also references U.S. Attorney General Jeff Sessions' comments during his 2017 confirmation hearings regarding these priorities and federal resource allocation. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to Congress.
HOUSE_OVERSIGHT_024706.jpg
This document is page 70 of a December 2017 Cannabis Investment Report by Ackrell Capital, bearing a House Oversight Bates stamp. It details the legal landscape of THC under the Controlled Substances Act (CSA), outlining the history of DEA regulations, the 2004 Ninth Circuit court ruling regarding synthetic vs. natural THC, and federal penalties for violations including asset seizure. The report also discusses the DEA's 2016 policy shift intended to expand registered cannabis cultivators beyond the University of Mississippi's long-standing monopoly, noting that while applications were accepted, no new registrations had been issued at the time of the report.
HOUSE_OVERSIGHT_024705.jpg
This document is page 69 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It provides a legal overview of the Controlled Substances Act (CSA), detailing the criteria for Schedule I-V drugs and specifically focusing on the classification and definition of marijuana as a Schedule I substance. The document bears a 'HOUSE_OVERSIGHT_024705' Bates stamp, suggesting it was included in evidence for a House Oversight Committee investigation, likely related to financial reviews.
HOUSE_OVERSIGHT_024703.jpg
This document is page 67 of a 2017 report by Ackrell Capital titled 'Chapter IV U.S. Legal Landscape.' It analyzes the conflict between U.S. state and federal laws regarding the cannabis industry, detailing regulatory requirements, banking difficulties, and taxation issues. It mentions policy shifts by the DOJ, Treasury, DEA, and FDA up to October 2017. The document bears a 'HOUSE_OVERSIGHT' bates stamp, suggesting it was part of a document production for a congressional investigation, though the page itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024701.jpg
This document is page 65 (Chapter IV) of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the history of CBD-specific legislation (Carly's Law, etc.) and the timeline of recreational legalization across various states between 2012 and 2016. While the document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a congressional investigation document production, the content is strictly an industry analysis of cannabis laws and contains no direct textual references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024700.jpg
This document is page 64 of a 'Cannabis Investment Report' dated December 2017, authored by Ackrell Capital. It provides a detailed overview of Medical Cannabis Laws in the United States, discussing the history of legalization starting with California in 1996, the legal distinction between 'prescribing' and 'recommending' under the CSA, qualifying medical conditions (listing over 50), and state-specific restrictions such as Pennsylvania's 2016 law. The document contains a Bates stamp 'HOUSE_OVERSIGHT_024700', indicating it was part of a document production to the House Oversight Committee, likely within a larger tranche of financial or investment records.
HOUSE_OVERSIGHT_024699.jpg
This document is a page from an Ackrell Capital report (Chapter IV: U.S. Legal Landscape) featuring a map and list of U.S. state cannabis laws as of January 2018. It categorizes states by Recreational Law, Medical Cannabis Law, CBD/Limited Law, or No Law. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to Congress (potentially related to financial investigations involving Epstein or related banks), the content itself is purely market research regarding the cannabis industry and contains no specific mention of Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024698.jpg
This page from a December 2017 Ackrell Capital report analyzes U.S. state laws regarding cannabis, categorizing them into medical, CBD/limited, and recreational frameworks. It notes that 47 out of 51 jurisdictions have enacted some form of cannabis law and discusses specific nuances in states like Florida, Delaware, and the District of Columbia.
HOUSE_OVERSIGHT_024697.jpg
This document is a page from a 2017 report by Ackrell Capital, LLC regarding the U.S. legal landscape for the cannabis industry. It discusses the conflict between federal prohibition and state legalization, noting that while federal policy restricts cannabis, 46 states permitted some use at the time. The document predicts a shift toward federal approval and legalization. It bears the stamp 'HOUSE_OVERSIGHT_024697', indicating it was part of a document production for a House Oversight Committee investigation, though the text itself contains no direct references to Jeffrey Epstein.
HOUSE_OVERSIGHT_024692.jpg
This document is page 56 of a December 2017 Cannabis Investment Report produced by Ackrell Capital, LLC. It analyzes risks regarding FDA approval and product liability, outlines the outlook for consumer products (flower, edibles, etc.), and discusses business solutions and software within the cannabis industry. The document bears a 'HOUSE_OVERSIGHT_024692' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024680.jpg
This document is page 44 of a Cannabis Investment Report published by Ackrell Capital in December 2017. It analyzes the 'Distribution Outlook' for the cannabis industry, discussing tax issues, regulatory challenges in states like Colorado, California, and Nevada, and compares US distribution models to international markets like Germany and Uruguay. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely produced as evidence for a congressional committee.
HOUSE_OVERSIGHT_024671.jpg
This document is page 35 of a 2017 industry report by Ackrell Capital regarding the cannabis industry. It details the economics and logistics of cannabis cultivation, comparing indoor vs. outdoor/greenhouse methods, and discusses legal challenges regarding interstate commerce. The document bears a 'HOUSE_OVERSIGHT_024671' stamp, indicating it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024670.jpg
This document is page 34 of a 'Cannabis Investment Report' published by Ackrell Capital in December 2017. The text details technical aspects of cannabis cultivation facilities, specifically comparing outdoor, greenhouse, and indoor growing methods, along with lighting and irrigation systems like hydroponics and aeroponics. While the content itself is purely industrial/financial, the Bates stamp 'HOUSE_OVERSIGHT_024670' indicates this document was obtained as evidence by the House Oversight Committee, potentially as part of a larger subpoena of financial records or investment portfolios relevant to an investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity